ALPMF - Astellas Pharma Non-GAAP EPS of ¥84.19 revenue of ¥1603.67B; initiates FY24 guidance April, 25 2024 03:54 AM Astellas Pharma Inc 2024-04-25 03:54:46 ET More on Astellas Pharma: Pfizer, Astellas first-line bladder cancer therapy accepted for review in China Astellas collaborates with Mass General Brigham for translational medicine Historical earnings data for Astellas Pharma For further details see: Astellas Pharma Non-GAAP EPS of ¥84.19, revenue of ¥1603.67B; initiates FY24 guidance